Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Affordable Insulin for All Act This bill addresses insulin affordability. For example, the bill requires the Department of Health and Human Services (HHS) to enter into agreements with insulin manufacturers to enable individuals with diagnosed diabetes to access Medicaid prices for insulin drugs. Additionally, Medicare and private insurance plans must cap cost-sharing at $10 per month for insulin drugs, and HHS must revise regulations to exclude payments made for insulin drugs from the denominator of the medical loss ratio. The bill also (1) eliminates a safe harbor for certain rebates, discounts, or price concessions for insulin drugs paid by a drug manufacturer to a pharmacy benefit manager for purposes of federal health care fraud and abuse laws; and (2) prohibits certain drug pricing activities related to supplemental rebates and spread pricing in Medicaid. The Government Accountability Office must report on the feasibility and affordability of direct manufacturing by the federal government.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2022 · first_quarter · Utilities
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Discussed bills to require cyber incident reporting by critical infrastructure sectors to the federal government - S. 2875, the Cyber Incident Reporting Act of 2021 (all provisions); H.R. 5440, the Cyber Incident Reporting for Critical Infrastructure Act of 2021 (all provisions); S. 2407, the Cyber Incident Notification Act of 2021 (all provisions); S. 3600, the Strengthening American Cybersecurity Act (all provisions); and H.R. 2471, the Consolidated Appropriations Act of 2022 (cyber incident reporting provision in Division Y - this was eventually signed into law). Discussed implementation of cyber incident reporting legislation included in the Consolidated Appropriations Act, 2022 (H.R. 2471). Discussed the importance of protecting the role of the Department of Energy (DOE) as the energy sectors risk management agency. Discussed comments APPA filed with DOE to its Request for Information, entitled Energy Sector Supply Chain Review. Discussed industry-wide transformer shortage and equipment supply chain challenges. Also discussed the need for more domestic production of electrical equipment. Discussed the strategic transformer reserve provision in section 20301 of H.R. 4521, the America COMPETES Act of 2022. Discussed several DOE grants APPA has received to support the cybersecurity posture of public power utilities, as well as to deploy cyber and cyber-physical solutions for public power utilities. Discussed public power utilities' efforts to transition to cleaner energy technologies, efforts to advance electrification, and modernize the grid. Discussed challenges public power utilities face in these efforts; and how programs in the Infrastructure Investment and Jobs Act could be helpful to public power utilities in their efforts. Discussed DOE's Notice of Intent (NOI) on Building a Better Grid Initiative To Upgrade and Expand the Nation's Electric Transmission Grid To Support Resilience, Reliability, and Decarbonization, which seeks to implement provisions from the Infrastructure Investment and Jobs Act, including the transmission needs study, the Transmission Facilitation Program, transmission corridor authority, and resiliency programs. Discussed implementation of the provisions in the Infrastructure Investment and Jobs Act by DOE on grid modernization, cybersecurity, resilience, and electric vehicles (EVs) (in coordination with the Department of Transportation (DOT)). Discussed implementation by DOE of provisions in H.R. 3684, the Infrastructure Investment and Jobs Act, that would be helpful to public power utilities, including provisions on cybersecurity, grid modernization, resilience, and the deployment of EV charging infrastructure (in conjunction with the DOT) (sections 11401, 40101, 40107, 40121, 40123, and 40124) and public powers transition to cleaner energy resources. Discussed the implementation of provisions in H.R. 3684, the Infrastructure Investment and Jobs Act, to provide grants to public power utilities and other entities to deploy charging infrastructure along designated corridors on the National Highway System. Discussed what public power is doing to enable EVs, including support for federal incentives included in H.R. 3684, the Infrastructure Investment and Jobs Act, and the ability of public power utilities to have access to those incentives. Discussed the role of public power utilities in helping deploy EV charging infrastructure. Also discussed public power EV rebate programs and EV fleet programs. In addition, discussed the need for flexibility and local decision making in the deployment of charging infrastructure and the importance of electric utility involvement in such deployment to ensure reliability. Discussed role of electric utilities in National Electric Vehicle Infrastructure (NEVI) program, including the need for engagement with utilities on state plans and siting decisions and the potential for federal funding to cover EV "make-ready" costs that would otherwise be borne by utility or site host. Discussed support for the inclusion of language in the Infrastructure Investment and Jobs Act to increase the Bonneville Power Administrations borrowing authority. Discussed support for the RD&D provisions in the Infrastructure Investment and Jobs Act to promote hydrogen, carbon capture and storage, and energy storage technologies. Discussed support for clean energy and research and development provisions in the Energy Act of 2020 (Division Z of H.R. 133, the Consolidated Appropriations Act, 2021). Discussed the importance of hydropower as an electricity resource for public power utilities and support for modernizing the hydropower licensing and relicensing process, including support for H.R. 1588, the Hydropower Clean Energy Future Act. Discussed the need for the reliable delivery of natural gas for electricity generation. Provided feedback on H.R. 5749, the Gas Consumer Emergency Market Protection Act (all provisions). Discussed natural gas futures price spike and impact to some public power utilities. Provided feedback on potential a Federal Energy Regulatory Commission (FERC)-related bill, on regional transmission organizations, joint ownership of transmission, the need for regulatory reform on federal transmission siting, and the streamlining of hydropower relicensing process. Discussed transmission issues, including inter-regional transmission planning, cost allocation, siting, and permitting. Also discussed rising transmission costs for public power utilities and the need for joint ownership of transmission by public power utilities. In addition, discussed issues with the interconnection queue in certain regional transmission markets. Discussed support for siting and permitting reform to enable the construction of clean energy infrastructure, including transmission.
Client expense: $270,000 · Firm income: Not reported
Government targets: Commodity Futures Trading Commission (CFTC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2020 · fourth_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID H.R. 8190 - Biosimilar Insulin Access Act of 2020 - Grothman - insulin biosimilar S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency S. 4134 - Increasing Access to Biosimilars Act of 2020 - Cornyn - CMS demonstration project; provider payments for providing biosimilars S. 4199 - Prescription Drug Pricing Reduction Act of 2020 - Grassley - lower drug prices in Medicare and Medicaid/ transparency S. 4439 - Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020 - Smith - COVID-19 drug be affordable and accessible Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; Executive Orders relating to international pricing, Part D rebates, insulin costs, and importation; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19, including vaccines and therapeutics; issues related to health care price transparency; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,400,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Council of Economic Advisers (CEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
2020 · fourth_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act H.R. 3630 - No Surprises Act
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID H.R. 8190 - Biosimilar Insulin Access Act of 2020 - Grothman - insulin biosimilar S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency S. 4134 - Increasing Access to Biosimilars Act of 2020 - Cornyn - CMS demonstration project; provider payments for providing biosimilars S. 4199 - Prescription Drug Pricing Reduction Act of 2020 - Grassley - lower drug prices in Medicare and Medicaid/ transparency S. 4439 - Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020 - Smith - COVID-19 drug be affordable and accessible Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; Executive Orders relating to international pricing, Part D rebates, insulin costs, and importation; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19, including vaccines and therapeutics; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,230,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2020 · third_quarter · Pharmacy
Opioids; CREATES Act; Drug Pricing HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration. HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin. HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain. HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods.
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office
2020 · second_quarter · Pharmacy
Opioids; CREATES Act; Drug Pricing H.R.6193 - 116th Congress Medication Access in Emergencies Act of 2020 Sponsor: Rep Pappas, Chris [D-NH-1] H.R.5691 - 116th Congress Transparency in Prescription Drug Advertising Act Sponsor: Rep Davids, Sharice [D-KS-3] H.R. 5894 - 116th Congress - Second Session Insulin Affordability Data Collection Act H.R. 5894 - 116th Congress - Second Session Transparency in Prescription Drug Advertising Act Sponsor: Rep. Sharice Davids (D-KS-03) H.R. 5927 - 116th Congress - Second Session Safe Medicine Act Sponsor: Rep. Bill Posey (R-FL-08) H.R. 5663 - 116th Congress - Second Session Safeguarding Therapeutics Act Sponsor: Rep Brett Guthrie (R-KY-02) H.R. 2477 - 116th Congress Beneficiary Enrollment Notification and Eligibility Simplification Act of 2019 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 5749 - 116th Congress - Second Session Affordable Insulin for All Act Sponsor: Rep. Charlie Crist (D-FL-13) H.R. 6731 - 116th Congress - Second Session Securing America's Pharmaceutical Supply Chain Act Sponsor: Rep. Pete Stauber (R-MN-08) H.R. 5982 - 116th Congress - Second Session Safe Medicine Act Sponsor: Rep. Bill Posey (R-FL-08)
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. Issues related to hospital inpatient blood glucose monitoring.
Client expense: $110,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2020 · second_quarter · Pharmacy
Opioid; CREATES Act; Drug Pricing; generic drugs; Civica Rx. H.R.6193 - 116th Congress (2019-2020)-Second Session Medication Access in Emergencies Act of 2020 Sponsor: Rep. Pappas, Chris [R-NH-1] (Introduced 03/11/2020) H.R. 5749- 116th Congress-Second Session Affordable Insulin for All Act Sponsor: Rep. Christ, Charlie [D-FL-13] (Introduced 02/04/2020)
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Pharmacy
Opioids; CREATES Act; Drug Pricing; H.R. 6193 - 116th Congress - Second Session Medication Access in Emergencies Act of 2020 Sponsor: Rep. Chris Pappas (D-NH-01) H.R. 5578 - 116th Congress - Second Session Recall Unsafe Drugs Act of 2020 Sponsor: Rep. Rosa DeLauro (D-CT-03) H.R. 5691 - 116th Congress - Second Session Sponsor: Insulin Affordability Data Collection Act H.R. 5894 - 116th Congress - Second Session Transparency in Prescription Drug Advertising Act Sponsor: Rep. Sharice Davids (D-KS-03) H.R. 5927 - 116th Congress - Second Session Safe Medicine Act Sponsor: Rep. Bill Posey (R-FL-08) H.R. 5663 - 116th Congress - Second Session Safeguarding Therapeutics Act Sponsor: Rep. Brett Guthrie (R-KY-02) R. 4712 - 116th Congress - First Session Fairness in Orphan Drug Exclusivity Act Sponsor: Rep. Madeleine Dean (D-PA-04) H.R. 2477 - 116th Congress - First Session Beneficiary Enrollment Notification and Eligibility Simplification Act of 2019 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 5749 - 116th Congress - Second Session Affordable Insulin for All Act Sponsor: Rep. Charlie Crist (D-FL-13) H.R. 6731 - 116th Congress - Second Session Securing America's Pharmaceutical Supply Chain Act Sponsor: Rep. Pete Stauber (R-MN-08) H.R. 5982 - 116th Congress - Second Session Safe Medicine Act Sponsor: Rep. Bill Posey (R-FL-08)
Client expense: $1,690,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
Opioids; CREATES Act; Drug Pricing HR 4712 (116th Congress), Fairness in Orphan Drug Exclusivity Act, by Rep. Madeleine Dean (D-PA). Amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs. HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration. HR 5663 (116th Congress), Safeguarding Therapeutics Act, by Rep. Brett Guthrie (R-KY). Give authority to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to destroy counterfeit devices. HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin. HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain. HR 5894 (116th Congress), Transparency in Prescription Drug Advertising Act, by Rep. Sharice Davids (D-KS). Directs the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs. HR 5927 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination. HR 5982 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination. HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods. HR 6731 (116th Congress), Securing Americas Pharmaceutical Supply Chain Act, by Rep. Pete Stauber (R-MN). Require executive agencies to purchase pharmaceuticals from the United States.
2020 · first_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6426 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office
Client expense: $350,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office
Client expense: $3,630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office